Phase I,open label study to assess the safety and tolerability of ZD6474 [vandetanib] in combination with 5-fluorouracil, leucovorin [folinic acid] and oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal adenocarcinoma
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Vandetanib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 24 Jan 2008 The expected completion date for this trial is now 1 Mar 2008.
- 10 Aug 2007 New trial record.